# Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)

> **NCT04344431** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Direction Centrale du Service de Santé des Armées** · enrollment: 100 (estimated)

## Conditions studied

- Covid-19

## Interventions

- **COMBINATION_PRODUCT:** Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)

## Key facts

- **NCT ID:** NCT04344431
- **Lead sponsor:** Direction Centrale du Service de Santé des Armées
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-14
- **Primary completion:** 2022-04
- **Final completion:** 2022-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04344431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04344431, "Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04344431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*